Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres Therapeutics management, will participate in a question and answer format discussion at the Goldman Sachs Global Healthcare Conference on Monday, June 12, 2023 at 4:40 p.m. PT.
An audio webcast of the presentation will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWSTTM, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.
The "Global Peptone Market Report and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
Global peptone market is forecasted to reach a value of $210 million by 2028 from $166.12 million in 2023, growing at a CAGR of...
The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer. This landmark...
The radiopharmaceuticals market size is expected to grow by USD 4.61 billion from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of 10.22% during the forecast period, according to Technavio Research. The market...
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that FDA has...
The "Global Liquid Dosage Excipients Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
The global study on the liquid dosage excipients assesses growth opportunities in the oral liquid and parenteral excipients...
Colorado Access announces the appointment of Jaime Moreno as the organization's new chief communications and member experience officer. This newly created position at Colorado Access is a testament to the organization's commitment to providing the...